[Event Report] The 2nd AMR Global Expert Meeting “Post G7 Ise-Shima Summit: Reflecting upon Japan’s National Action Plan and Addressing Next Steps for Global Antimicrobial Resistance” (July 21, 2017)
date : 7/21/2017
Tags: AMR
![](http://www.hgpi.org/photo/20170721welcoming%20remarks.jpg)
Kuniaki Miyake (Director, Tuberculosis and Infectious Diseases Control
![](http://www.hgpi.org/photo/20170721keynote%20address1.jpg)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases/
Professor, Department of Microbiology and Infectious Diseases, Toho University)
Professor Tateda gave a keynote address on the future direction of infectious diseases treatments in the AMR Era. He emphasized the goal of promoting the appropriate use of antimicrobials, rather than just aiming to meet numerical targets and figures. He also pointed out the importance of education and efforts to spread knowledge among primary care physicians in order to enable them to practice the appropriate use of antimicrobials.
![](http://www.hgpi.org/photo/20170721keynote%20address2.jpg)
Panel Discussion 1
“G7 Ise-Shima Summit’s Achievements and Further Role to Combat AMR”
The discussion in Session 1 reflected on the changes made during the past year following the G7 Ise-Shima summit both globally and locally. The Panel elaborated on the complicated issue of the new framework for public-private partnerships (PPP) needed for AMR R&D policies.
![](http://www.hgpi.org/photo/20170721panel1.jpg)
![](http://www.hgpi.org/photo/20170721panel1-1.jpg)
• Gary M. Cohen (Executive Vice President and President, Global Health and Development, Becton, Dickinson and Company)
• Jayasree K. Iyer (Executive Director, Access to Medicine Foundation)
• Paul Schaper (Executive Director, Global Public Policy, Merck & Co., Inc., Kenilworth, N.J., U.S.A.)
• Naoko Yamamoto (Senior Assistant Minister for Global Health, MHLW)
Mayuka Yamazaki (Project Assistant Professor, Global Health Policy, Faculty of Medicine, The University of Tokyo)
Panel Discussion 2
“Challenges and Next Agendas in Japan’s National Action Plan”
In this session, experts had a focused discussion on the remaining challenges and future agenda related to Japan’s National Action Plan, including incentives to foster antimicrobial development as well as possible frameworks for the government-industry-academia partnerships critical to that process.
![](http://www.hgpi.org/photo/20170721panel2.jpg)
![](http://www.hgpi.org/photo/20170721panel2-1.jpg)
• Norio Ohmagari (Vice Director, National Center for Global Health and Medicine / Director, Disease Control and Prevention Center(DCC) / Director, International Health Care Center at DCC)
• Takuko Sawada (Director of the Board, Senior Executive Officer, Senior Vice President, Corporate Strategy Division, Shionogi & Co., Ltd.)
• Kazuhiko Mori (Director, Evaluation and Licensing Division, MHLW)
• Katsunori Yanagihara (Professor, Department of Laboratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University)
Ryoji Noritake
President, Health and Global Policy Institute (HGPI)
Keizo Takemi (Member of the House of Councillors)
Building off of his long history of work in the global health field, including on AMR, Mr. Takemi spoke about the complex and pressing issue of AMR, including the importance of working to resolve issues related to the development and creation of new antimicrobials specifically to address AMR, through collaborations among the Cabinet Secretariat (including the Coordination Office of Measures on Emerging Infectious Diseases, and the Healthcare Policy Office), MHLW, the Ministry of Foreign Affairs (MOFA), the private sector, and academia.
![](http://www.hgpi.org/photo/20170721Closing%20Address.jpg)
Top Research & Recommendations Posts
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Publication Report] Guidance on Patient and Public Involvement (PPI) in Health Policymaking: Necessary Initiatives and Good Examples from the Public and Government (March 31, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Research Report] Healthcare DX Project Research Report of Interviews ”Expectations for the Coming Era of Healthcare DX from People Living with Health Concerns” (June 10, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Policy Recommendations] Patient and Public Involvement (PPI) Support Project “Promoting PPI in the Policymaking Process” (May 14, 2024)
- [Public Comment Submission] “The Fifth Fundamental Plan for Establishing a Sound Material-Cycle Society (Draft)” (May 22, 2024)
- [Policy Recommendations] Recommendation for the Basic Policy on Economic and Fiscal Management and Reform 2024 (June 11, 2024)
Featured Posts
-
2024-06-21
[Event Report] HGPI Special Seminar – HGPI Celebrates its 20th Anniversary: Reflecting on HGPI’s Journey from the Past to the Future (January 16, 2024)
-
2024-06-25
[Public Comment Submission] Web based consultations on NCDs and mental health by World Health Organization (June 25, 2024)
-
2024-06-26
[Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
-
2024-06-26
[Registration Open] (Webinar) The 127th HGPI Seminar: Current Issues and Future Prospects in Establishing a Health System and Protecting Public Health Through Policy (July 18, 2024)
-
2024-07-01
[Registration Open] Meaningful Involvement Promotion Project Online Expert Meeting “Shaping the Future of Health Policy with People with Lived Experience and Citizens” (July 26, 2024)